



## OSE Immunotherapeutics to present at 2016 MedStart Up Days New York City, October 27<sup>th</sup> & 28<sup>th</sup>, 2016

**Nantes, October 24, 2016 - OSE Immunotherapeutics SA** (ISIN: FR0012127173; Mnémo: OSE), a biotechnology company developing immunotherapies of activation and regulation in immuno-oncology, auto-immune diseases and transplantation, today announces it will be featured as a presenting company at MedStart Up Days, sponsored by Galien Foundation and Business France, to be held in New York City on October 27<sup>th</sup> & 28<sup>th</sup> (Alexandria Center For Life Science - 450 East 29th Street).

During the presentation, Alexis Peyroles, COO of OSE Immunotherapeutics, will present the company, including lead product, Tedopi® - a combination of -10 neo- epitopes selected and optimized from five tumor antigens - which is currently undergoing U.S. and EU pivotal Phase III clinical trial testing for non-small cell lung cancer and FR104 - CD28-antagonist - in clinical development by Johnson & Johnson, for autoimmune disorders.

*“Our “first-in-class” portfolio, targeting high growth markets in immuno-oncology and immunotherapy together with our partnership with Johnson & Johnson on FR104, support the company’s strategic development, especially in the U.S.”, comments Alexis Peyroles, Chief Operating Officer of OSE Immunotherapeutics. “Specifically, Tedopi®, FR104, as well as our early stage assets are poised to create shareholder value.”*

### **Details of the presentation:**

**Day and time:** Thursday, October 27<sup>th</sup>, 2016 at 8:30am EST

**Place:** Alexandria Center For Life Science - 450 East 29th Street, New York, NY 10016

**More information:** <https://www.eventbrite.com/e/medstartup-partnering-by-business-france-the-galien-foundation-registration-28612905972?aff=erelexpmlt>

### **ABOUT MEDSTART UP DAYS**

The MedStartUp Days are specifically designed to gather experts and entities from life sciences, technology, venture, policy research and more to explore the future of life sciences and digital health. Each year, hundreds of attendees meet in New York for this two-day event.

#### **Business France**

Business France is the national agency supporting the international development of the Economy of France, responsible to foster export growth by French businesses, as well as promoting and facilitating international investment in France.

Business France promotes French companies, brand visibility and nationwide attractiveness.

#### **Galien Foundation**

The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.

### **ABOUT OSE IMMUNOTHERAPEUTICS**

*Our ambition is to become a world leader in activation and regulation immunotherapies*

OSE Immunotherapeutics is a biotechnology company led by world-class immunologists and focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology, auto-immune diseases and transplantation.

The company has a balanced portfolio of first-in-class products with a diversified risk profile ranging from clinical phase 3 registration trials to R&D:

- **Tedopi<sup>®</sup>**, a combination of 10 optimized neo-epitopes to induce specific T activation in immuno-oncology - **currently in registration Phase 3 trial advanced NSCLC HLA A2+ patients EU /US** - Orphan Status in the US - **registration expected in 2019** - a Phase 2 with Tedopi<sup>®</sup> in combination with a checkpoint inhibitor in NSCLC is considered in 2017 - the product is also considered in other cancer indications.
- **FR104**, CD28-antagonist in immunotherapy - **Phase 1 trial completed** - targets autoimmune diseases and transplantation - **licensed to J&J** to pursue clinical development
- **Effi-7**, interleukin receptor 7 antagonist - **in preclinical development** for inflammatory bowel diseases and other autoimmune diseases
- **Effi-DEM**, new generation checkpoint inhibitor targeting the **SIRP- $\alpha$  receptor on the strategic SIRP- $\alpha$ /CD47 pathway** - **in preclinical development** for immuno-oncology
- **R&D**: candidates targeting new receptors in immuno-oncology

The portfolio's blockbuster potential gives OSE Immunotherapeutics the ability to enter into global agreements at different stages of development with major pharmaceutical players, such as the one signed for FR104 with the J&J Group.

Immunotherapy is a highly promising and growing market. By 2023 Immunotherapy of cancer could represent nearly 60% of treatments against less than 3% at present \* and the projected market is estimated at \$67 billion in 2018 \*\*.

There are more than 80 autoimmune diseases that represent a significant market including major players in the pharmaceutical industry with sales upper \$10 billion for the main products. The medical need is largely unmet and requires the provision of new innovative products involved in the regulation of the immune system.

\*Citi Research Equity  
\*\*BCC Research

More information : <http://ose-immuno.com>

Click and follow us on Twitter and LinkedIn



## Contacts

### **OSE Immunotherapeutics**

Dominique Costantini, CEO

[dominique.costantini@ose-immuno.com](mailto:dominique.costantini@ose-immuno.com)

+33 613 207 749

Maryvonne Hiance, Vice-Chairman and Director of Strategy

[maryvonne.hiance@ose-immuno.com](mailto:maryvonne.hiance@ose-immuno.com)

+33 680 060 183

Alexis Peyroles, COO, Finance, BD & Operations

[alexis.peyroles@ose-immuno.com](mailto:alexis.peyroles@ose-immuno.com)

+33 611 511 977

Bernard Vanhove, COO, R&D, International scientific collaborations

[Bernard.vanhove@ose-immuno.com](mailto:Bernard.vanhove@ose-immuno.com)

+33 675 414 008

### **Contacts media**

**Alize RP**

Florence Portejoie & Caroline Carmagnol

[oseimmuno@alizerp.com](mailto:oseimmuno@alizerp.com)

+33 647 389 004

### **LifeSci Advisors**

Chris Maggos

[chris@lifesciadvisors.com](mailto:chris@lifesciadvisors.com)

+41 79 367 6254

### **Acorelis**

Gilles Petitot

+33 620 276 594

[gilles.petitot@acorelis.com](mailto:gilles.petitot@acorelis.com)

## **Forward-looking statements**

This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.

These forward-looking statements include statements typically using conditional and containing verbs such as "expect", "anticipate", "believe", "target", "plan", or "estimate", their declensions and conjugations and words of similar import.

Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks



could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance.

This press release includes only summary information and should be read with the OSE Immunotherapeutics Reference Document filed with the AMF on 8 June 2016 under the number R.16-052, the consolidated financial statements and the management report for the fiscal year 2015, as well as the Merger Document registered with the AMF on 26 April 2016 under number E.16-026, all available on the OSE Immunotherapeutics' website.

Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.